Experience with fampridine in clinical practice: analysis of a possible marker of clinical response.

Purpose Of The Study: Approximately 85% of patients with multiple sclerosis experience reduced mobility, which negatively affects quality of life. Fampridine is the first symptomatic treatment aimed at improving gait. We analyzed effectiveness and tolerance in clinical practice.